Table 1. Analysis of Risk Factors for Maculopathy in Patients Treated With BBBD Therapya.
| Risk factor | Maculopathy | Model 1 | Model 2 | |||
|---|---|---|---|---|---|---|
| Yes (n = 32) | No (n = 33) | OR (95% CI) | P value | OR (95% CI) | P value | |
| Female | 16 (50.0) | 9 (27.3) | 1.37 (0.30-6.31) | .68 | 1.74 (0.38-8.00) | .48 |
| Age at first treatment, mean (SD), y | 51.6 (16.7) | 40.2 (17.5) | 1.05 (0.99-1.11) | .09 | 1.03 (0.98-1.09) | .22 |
| No. of BBBD treatment sessions | 26.0 | 13.8 | 1.30 (1.12-1.50) | .001b | 1.27 (1.11-1.46) | .001b |
| Intraocular lymphoma | 6 (18.8) | 3 (9.1) | 3.00 (0.25-36.72) | .39 | 2.36 (0.21-27.10) | .49 |
| Systemic chemotherapy | ||||||
| Methotrexate | 21 (65.6) | 12 (36.4) | 1.28 (0.20-8.12) | .79 | NA | NA |
| Carboplatin | 17 (53.1) | 18 (54.5) | 0.21 (0.04-1.09) | .06 | NA | NA |
| Tumor diagnosis | ||||||
| PCNSL | 21 (65.6) | 12 (36.4) | NA | NA | 1 [Reference] | NA |
| CNS glioma | 8 (25.0) | 13 (39.4) | NA | NA | 0.99 (0.15-6.53) | .99 |
| Pineal tumor | 1 (3.1) | 5 (15.2) | NA | NA | 0.33 (0.02-6.67) | .47 |
| Other | 2 (6.3) | 3 (9.1) | NA | NA | 2.72 (0.12-62.87) | .53 |
Abbreviations: BBBD, blood-brain barrier disruption; CNS, central nervous system; NA, not applicable; OR, odds ratio; PCNSL, primary central nervous system lymphoma.
a
Data are presented as number (percentage) of patients unless otherwise indicated. Two logistic regression models are presented because of high multicollinearity between systemic chemotherapy agent and tumor diagnosis.
b
P < .05.